OraSure Technologies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

OraSure Technologies hat ein Gesamteigenkapital von $426.3M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $467.6M bzw. $41.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$263.77m
Eigenkapital	US$426.25m
Gesamtverbindlichkeiten	US$41.31m
Gesamtvermögen	US$467.56m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: EP3Die kurzfristigen Aktiva des Unternehmens ($348.5M) übersteigen seine kurzfristigen Passiva ($29.1M).

Langfristige Verbindlichkeiten: EP3Die kurzfristigen Vermögenswerte des Unternehmens ($348.5M) übersteigen seine langfristigen Verbindlichkeiten ($12.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: EP3 ist schuldenfrei.

Schulden abbauen: EP3 hat in den letzten 5 Jahren keine Schulden gemacht.

Schuldendeckung: EP3 hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: EP3 hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

OraSure Technologies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

New minor risk - Shareholder dilution

OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings released: US$0.048 loss per share (vs US$0.37 profit in 1Q 2023)

New minor risk - Shareholder dilution

OraSure Technologies, Inc., Annual General Meeting, May 14, 2024

OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$0.73 (vs US$0.25 loss in FY 2022)

OraSure Technologies, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Investor sentiment improves as stock rises 22%

OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023

Third quarter 2023 earnings released: EPS: US$0.15 (vs US$0.073 in 3Q 2022)

OraSure Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 27%

New major risk - Share price stability

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings released: US$0.065 loss per share (vs US$0.26 loss in 2Q 2022)

OraSure Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

OraSure Technologies, Inc. Announces Election of Robert W. McMahon to its Board of Directors, Effective July 31, 2023

OraSure Technologies, Inc. Announces Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

Investor sentiment improves as stock rises 18%

Chief Financial Officer recently bought €460k worth of stock

Investor sentiment deteriorates as stock falls 20%

Orasure Technologies, Inc. Provides Earnings Guidance for the Second Quarter 2023

First quarter 2023 earnings released: EPS: US$0.37 (vs US$0.28 loss in 1Q 2022)

OraSure Technologies, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.25 loss per share (vs US$0.32 loss in FY 2021)

OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2023

OraSure Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023

High number of new directors

OraSure Technologies, Inc. Announces Executive Changes

Third quarter 2022 earnings released: EPS: US$0.073 (vs US$0.21 loss in 3Q 2021)

OraSure Technologies, Inc. Reports Goodwill and Long-Lived Assets Impairment Charges for the Third Quarter Ended September 30, 2022

Orasure Technologies Receives General Clearance for Its ORAcollect--Dx Device for over the Counter Use from the U.S. Food and Drug Administration

OraSure Technologies, Inc. Announces InteliSwab Covid-19 Rapid Test Now Available in Amazon’s Online Store

OraSure Technologies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Independent Director recently bought €200k worth of stock

Independent Chairman of the Board recently bought €53k worth of stock

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.019 loss in 2Q 2021)

OraSure Technologies, Inc. Announces CFO Changes

OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2022

OraSure Technologies, Inc. to Report Q2, 2022 Results on Aug 09, 2022

OraSure Technologies, Inc. Announces Executive Changes

OraSure Technologies LaunchesNewProduct for Microbiome Researchers to Study DNA and RNA

OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell 2000 Value-Defensive Index

OraSure Technologies, Inc. Announces Resignation of Agnieszka M. Gallagher as Executive Vice President, General Counsel and Chief Compliance Officer, Effective June 25, 2022

OraSure Technologies, Inc. Appoints Carrie Eglinton Manner as President, Effective June 4, 2022

OraSure Technologies, Inc. Announces That Its InteliSwab® Covid-19 Rapid Tests Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.053 profit in 1Q 2021)

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

OraSure Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Orasure Technologies, Inc. Announces Inteliswab® Covid-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New Inteliswab® Connect Reporting App

OraSure Technologies, Inc. Updates Revenue Guidance for the Fourth Quarter of 2021

High number of new directors

High number of new directors

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.015 profit in 3Q 2020)

OraSure Technologies, Inc. to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

CFO & Principal Accounting Officer Roberto Cuca has left the company

Orasure Technologies, Inc. Provides Revenue Guidance for the Third Quarter and Fiscal Year 2021

Second quarter 2021 earnings released: US$18.95 loss per share (vs US$0.16 loss in 2Q 2020)

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

Director Mara Aspinall has joined 5th company board

OraSure Technologies, Inc.(NasdaqGS:OSUR) dropped from Russell Small Cap Comp Growth Index

OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescription, Professional and Prescription Use

OraSure Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: EPS US$0.053 (vs US$0.12 loss in 1Q 2020)

Full year 2020 earnings released: US$0.22 loss per share (vs US$0.27 profit in FY 2019)

Revenue beats expectations